CASP3 and cancer: The IHCpAkt+p62 scoring system established in this study is based on the fact that cleaved caspase-3/caspase-3 ratios can substitute for LD-derived IC50 for assessing cancer cell chemoresistance against cisplatin (Figure 5A and 5B).